Dinutuximab: first global approval.

Dinutuximab: first global approval.

Item
http://www.wikidata.org/entity/Q38458853
Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.ST6GALNAC5 Expression Decreases the Interactions between Breast Cancer Cells and the Human Blood-Brain Barrier.Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.Complement as a Biological Tool to Control Tumor Growth
P2860

Dinutuximab: first global approval.

Item
http://www.wikidata.org/entity/Q38458853
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dinutuximab: first global approval.
@en
type
label
Dinutuximab: first global approval.
@en
prefLabel
Dinutuximab: first global approval.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P356
P1433
P1476
Dinutuximab: first global approval.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698